Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2006

View Archived Issues

Q2 review at Schering-Plough

Phase III study of MyVax in follicular NHL recommended to continue

Exclusivity period expires for business combination of BCY LifeSciences with Pipex

NicAlert to be used in new smoking cessation study

NAP treatment beneficial in model of neonatal encephalopathy

Caspase inhibition with z-VAD-FMK attenuates immediate islet mass loss in transplanted mice

Annamycin and WP-744 selectively induce apoptosis of donor T cells allowing transplant tolerance

Cardioprotective effects of a new amphiphilic spin-trap derived from PBN

Protectan CBLB-502 demonstrates effectiveness in ARS in primates

Phyton Biotech to develop Iplex manufacturing process

New Novavax vaccine to protect against H5N1 clade 2 influenza virus

AMDL compiles FDA requested data for DR-70 cancer test

sBLA filed for CAIV-T in young children

Receptor BioLogix acquires cancer vaccine Insegia

Phase III PolyHeme study completes enrollment

European orphan drug status recommended for BiovaxID in follicular lymphoma

Pozen to submit full response to Trexima approvable letter in Q4

Phase I study findings for IV DNA + protein vaccine DP6-001

Tavocept fails to meet endpoints in phase III neuropathy trials

Schering hit by insufficient results for sargramostim and Ultravist recall

Temodal approved in Japan for malignant glioma

Remicade approved in Europe as monotherapy for psoriatic arthritis

Chantix now available in U.S.

Novel therapeutic agents for HIV infection reported by Tibotec, Pfizer

Novel agents for HCV and gastric emptying cited in recent patents

European approval for NovoRapid in pregnant women with diabetes

Bristol-Myers Squibb patents novel coagulation Factor VIIa inhibitors

Vernalis reports on novel PDEIII/IV inhibitors with bronchodilator and antiinflammatory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...